These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24905899)

  • 1. Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicine.
    Lamba G; Zaidi SK; Luebbers K; Verschraegen C; Stein GS; Rosmarin A
    J Cell Biochem; 2014 Oct; 115(10):1669-72. PubMed ID: 24905899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic targeting and personalized approaches for AML.
    Roboz GJ
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics in acute myeloid leukemia.
    Plass C; Oakes C; Blum W; Marcucci G
    Semin Oncol; 2008 Aug; 35(4):378-87. PubMed ID: 18692688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
    Kogan AA; Lapidus RG; Baer MR; Rassool FV
    Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia].
    Li X; Zhu L; Ye X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):387-394. PubMed ID: 27868412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
    Yang X; Wong MPM; Ng RK
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Wouters BJ; Delwel R
    Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia.
    Weng H; Lal K; Yang FF; Chen J
    Cancer Genet; 2015 May; 208(5):225-9. PubMed ID: 25686674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.
    Garciaz S; N'guyen Dasi L; Finetti P; Chevalier C; Vernerey J; Poplineau M; Platet N; Audebert S; Pophillat M; Camoin L; Bertucci F; Calmels B; Récher C; Birnbaum D; Chabannon C; Vey N; Duprez E
    Clin Epigenetics; 2019 Oct; 11(1):141. PubMed ID: 31606046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
    Kim TK; Gore SD; Zeidan AM
    Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
    Paul TA; Bies J; Small D; Wolff L
    Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.
    Kelm RJ; Lamba GS; Levis JE; Holmes CE
    J Cell Biochem; 2018 Feb; 119(2):2073-2083. PubMed ID: 28834593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.